These cancer-activating mutations, which occur in the tyrosine kinase domain of the EGFR, were classified as oncogenic drivers of non-small cell lung cancer (NSCLC), one of the most lethal cancers in the world [43]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.